BACKGROUND: Hypoglycemia and hypoglycemia unawareness are common in long-standing type 1 diabetes (T1D). This pilot study examined the real-world use of a smartphone application (app), which receives meter readings and logs hypoglycemic symptoms, causes, and treatments to reduce hypoglycemia. METHODS: Adults with T1D and recent hypoglycemia synchronized their glucose meter to their smartphone and used the Joslin HypoMap™ app powered by Glooko to track hypoglycemic events. At baseline, and after 6 and 12 weeks of using the app, a blinded continuous glucose monitor (CGM; Dexcom G4) was used for 2 weeks and surveys administered. RESULTS: Participants (n = 22) at baseline had mean (SD) age 43 (14) years, duration of diabetes 26 (13) years, A1c 8.0% (0.87) and 21/22 had reduced hypoglycemia awareness per Clarke Hypoglycemia Unawareness survey scores; 13 (59%) were "CGM completers" (CGM data available at baseline and follow-up). Most noncompletion related to time required/difficulties using the mobile app. After 6 weeks, 8/13 completers (62% of CGM completers, 36% of total participants) had reduced daytime minutes with glucose <54 mg/dL (mean ↓331 minutes) and 10/13 (77% of CGM completers; 45% of total participants) had reduced time ≤ 70 mg/dL (mean ↓449 minutes). This was not sustained at 12 weeks, at which time half of the completers had less time ("improved"). Five participants reported improved hypoglycemia awareness; 9 stated the app helped them better recognize hypoglycemia. CONCLUSIONS: Use of this phone app has the potential to help reduce daytime hypoglycemia in a subset of T1D adults with reduce hypoglycemia awareness; larger studies are needed.
BACKGROUND:Hypoglycemia and hypoglycemia unawareness are common in long-standing type 1 diabetes (T1D). This pilot study examined the real-world use of a smartphone application (app), which receives meter readings and logs hypoglycemic symptoms, causes, and treatments to reduce hypoglycemia. METHODS: Adults with T1D and recent hypoglycemia synchronized their glucose meter to their smartphone and used the Joslin HypoMap™ app powered by Glooko to track hypoglycemic events. At baseline, and after 6 and 12 weeks of using the app, a blinded continuous glucose monitor (CGM; Dexcom G4) was used for 2 weeks and surveys administered. RESULTS:Participants (n = 22) at baseline had mean (SD) age 43 (14) years, duration of diabetes 26 (13) years, A1c 8.0% (0.87) and 21/22 had reduced hypoglycemia awareness per Clarke Hypoglycemia Unawareness survey scores; 13 (59%) were "CGM completers" (CGM data available at baseline and follow-up). Most noncompletion related to time required/difficulties using the mobile app. After 6 weeks, 8/13 completers (62% of CGM completers, 36% of total participants) had reduced daytime minutes with glucose <54 mg/dL (mean ↓331 minutes) and 10/13 (77% of CGM completers; 45% of total participants) had reduced time ≤ 70 mg/dL (mean ↓449 minutes). This was not sustained at 12 weeks, at which time half of the completers had less time ("improved"). Five participants reported improved hypoglycemia awareness; 9 stated the app helped them better recognize hypoglycemia. CONCLUSIONS: Use of this phone app has the potential to help reduce daytime hypoglycemia in a subset of T1D adults with reduce hypoglycemia awareness; larger studies are needed.
Entities:
Keywords:
apps; hypoglycemia; hypoglycemia awareness; mobile; type 1 diabetes
Authors: Elizabeth J Mayer-Davis; Jean M Lawrence; Dana Dabelea; Jasmin Divers; Scott Isom; Lawrence Dolan; Giuseppina Imperatore; Barbara Linder; Santica Marcovina; David J Pettitt; Catherine Pihoker; Sharon Saydah; Lynne Wagenknecht Journal: N Engl J Med Date: 2017-04-13 Impact factor: 91.245
Authors: Andrew I Geller; Nadine Shehab; Maribeth C Lovegrove; Scott R Kegler; Kelly N Weidenbach; Gina J Ryan; Daniel S Budnitz Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Daniel J Cox; Boris Kovatchev; Dragomir Koev; Lidia Koeva; Svetoslav Dachev; Dimitar Tcharaktchiev; Anastassia Protopopova; Linda Gonder-Frederick; William Clarke Journal: Int J Behav Med Date: 2004
Authors: Ruth S Weinstock; Dongyuan Xing; David M Maahs; Aaron Michels; Michael R Rickels; Anne L Peters; Richard M Bergenstal; Breanne Harris; Stephanie N Dubose; Kellee M Miller; Roy W Beck Journal: J Clin Endocrinol Metab Date: 2013-06-12 Impact factor: 5.958
Authors: S A Little; L Leelarathna; S M Barendse; E Walkinshaw; H K Tan; A Lubina Solomon; N de Zoysa; H Rogers; P Choudhary; S A Amiel; S R Heller; M Evans; D Flanagan; J Speight; J A M Shaw Journal: Diabetes Metab Res Rev Date: 2014-03 Impact factor: 4.876
Authors: Neda Laiteerapong; Andrew J Karter; Jennifer Y Liu; Howard H Moffet; Rebecca Sudore; Dean Schillinger; Priya M John; Elbert S Huang Journal: Diabetes Care Date: 2011-06-02 Impact factor: 19.112
Authors: Stefanie M P A Rondags; Maartje de Wit; Maurits W van Tulder; Michaela Diamant; Frank J Snoek Journal: BMC Endocr Disord Date: 2015-08-21 Impact factor: 2.763
Authors: María Begoña Martos-Cabrera; Almudena Velando-Soriano; Laura Pradas-Hernández; Nora Suleiman-Martos; Guillermo A Cañadas-De la Fuente; Luis Albendín-García; José L Gómez-Urquiza Journal: J Clin Med Date: 2020-03-04 Impact factor: 4.241